HyperGAM antibody data

UNVX presented data from Phase I/II tests showing sufficient generation of killing antibodies to treat lung infection in cystic fibrosis, and announced it will start Phase II trials by mid-1994 in CF patients experiencing acute exacerbations of their Pseudomonas infections. ...